Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
Steven G DuBoisMark D KrailoJulia L Glade BenderAllen BuxtonNadia N Issa LaackRobert Lor RandallHelen X ChenNita L SeibelMatthew BoronStephanie A TerezakisChristine Hill-KayserAndrea HayesJoel M ReidLisa TeotDinesh RakhejaRichard B WomerCarola ArndtStephen L LessnickBrian D CromptonEdward Anders KolbHeike Daldrup-LinkEric EutslerDamon R ReedKatherine A JanewayRichard G GorlickPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Ganitumab added to interval-compressed chemotherapy did not significantly reduce the risk of EFS event in patients with newly diagnosed metastatic Ewing sarcoma, with outcomes similar to prior trials without IGF-1R inhibition or interval compression. The addition of ganitumab may be associated with increased toxicity.